What is the price target for CBAY stock?
16 analysts have analysed CBAY and the average price target is 33.15 USD. This implies a price increase of 2.06% is expected in the next year compared to the current price of 32.48.
CYMABAY THERAPEUTICS INC (CBAY) Forecast, Price Target & Analyst Ratings
NASDAQ:CBAY • US23257D1037
Current stock price
32.48 USD
+0.01 (+0.03%)
At close:
32.48 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYMABAY THERAPEUTICS INC (CBAY).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 13, 2024
- Period
- Q1 / 2024
- EPS Estimate
- -$0.32
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$33.15
Upside
+ 2.06%
From current price of $32.48 to mean target of $33.15, Based on 16 analyst forecasts
Low
$32.83
Median
$33.15
High
$34.13
Price Target Revisions
1 Month
5.69%
3 Months
31.31%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for CBAY. The average price target is 33.15 USD. This implies a price increase of 2.06% is expected in the next year compared to the current price of 32.48.
The average price target has been revised upward by 31.31% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
53.75%
CBAY was analyzed by 16 analysts. The buy percentage consensus is at 54. So analysts seem to be rather neutral about CBAY.
In the last month the buy percentage fell by 33 points. So the trust of analysts is decreasing.
CBAY was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-02-29 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-02-20 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-02-14 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2024-02-14 | UBS | Downgrade | Buy -> Neutral |
| 2024-02-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-02-13 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-02-13 | JonesTrading | Downgrade | Buy -> Hold |
| 2024-02-13 | BTIG | Downgrade | Buy -> Neutral |
| 2024-02-13 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-02-13 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2024-02-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-02-12 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-12-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-11-08 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-09-26 | UBS | Maintains | Buy -> Buy |
| 2023-09-08 | BTIG | Maintains | Buy -> Buy |
| 2023-09-08 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-09-08 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-09-07 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2023-09-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-31 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 13, 2024
- Period
- Q1 / 2024
- EPS Estimate
- -$0.32
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -10.21%
- Number of Analysts
- 11
Next Earnings Revisions
Revenue (1 Month)
-100.00%
Revenue (3 Months)
N/A
EPS (1 Month)
0.71%
EPS (3 Months)
-0.67%
Next Earnings Summary
CBAY is expected to report earnings on 5/13/2024. The consensus EPS estimate for the next earnings is -0.32 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.073M | 11.961M -61.51% | 116.93M 877.59% | 252.7M 116.11% | 500.89M 98.22% | 735.79M 46.90% | 1.021B 38.76% | 1.159B 13.52% | |||
| EBITDA YoY % growth | -86.89M -64.94% | -92.4M -6.34% | -100.998M -9.31% | -167.754M -66.10% | -89.332M 46.75% | 82.11M 191.92% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.58M -64.28% | -93.11M -6.31% | -101.679M -9.20% | -173.058M -70.20% | -111.906M 35.34% | 6.898M 106.16% | 209.55M 2,937.84% | 408.44M 94.91% | 703.7M 72.29% | 810.98M 15.25% | |
| Operating Margin | N/A | N/A | -327.23% | -1,446.85% | -95.70% | 2.73% | 41.84% | 55.51% | 68.92% | 69.97% | |
| EPS YoY % growth | -1.26 -68.00% | -1.21 3.97% | -0.97 19.83% | -1.46 -50.27% | -1.06 27.14% | -0.31 70.86% | 1.13 463.96% | 2.38 111.59% | 4.50 88.78% | 4.83 7.41% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 -10.21% | -0.35 -3,419.00% | -0.43 -33.48% | -0.43 -23.13% | -0.83 -158.51% | -0.65 -85.51% | -0.61 -43.28% | -0.79 -82.25% | -0.43 48.15% | -0.20 68.75% | -0.02 96.67% |
| Revenue Q2Q % growth | -100.00% | 852.863K | 7.753M 13,501.75% | 7.646M | 7.646M | 15.788M 1,751.18% | 28.858M 272.22% | 39.817M 420.76% | 70.254M 818.83% | 94.223M 496.80% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -37.509M -39.54% | -41.743M -41,642.65% | -50.223M -55.92% | -51.796M -21.88% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
18.90%
EPS Next 5 Year
34.83%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
99.83%
Revenue Next 5 Year
87.60%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
41.95%
EBIT Next 5 Year
N/A
CYMABAY THERAPEUTICS INC / CBAY Forecast FAQ
Can you provide the upcoming earnings date for CYMABAY THERAPEUTICS INC?
CYMABAY THERAPEUTICS INC (CBAY) will report earnings on 2024-05-13, after the market close.
What are the consensus estimates for CBAY stock next earnings?
The consensus EPS estimate for the next earnings of CYMABAY THERAPEUTICS INC (CBAY) is -0.32 USD and the consensus revenue estimate is 0 USD.
Can you provide the analyst count for CYMABAY THERAPEUTICS INC stock?
The number of analysts covering CYMABAY THERAPEUTICS INC (CBAY) is 16.